SUMMARY
- MCCPDC, under Mark Cuban's stewardship, is making waves in the generic drugs sector with its innovative business model.
- The company's transparent pricing system and partnerships with insurers promise significant benefits for consumers, particularly the uninsured.
- Despite challenges, MCCPDC's bold plans to expand into the insulin and biosimilars market underscore its potential to continue disrupting the industry.
![broken image](http://custom-images.strikinglycdn.com/res/hrscywv4p/image/upload/c_limit,fl_lossy,h_9000,w_1200,f_auto,q_auto/9596329/927519_469694.png)
Mark Cuban's Cost Plus Drug Company (MCCPDC) continues to make remarkable strides in the generic drugs sector, standing as a formidable disruptor in the industry. With its booming customer base exceeding 1.5 million, the company's presence is increasingly hard to ignore.
Pioneering a revolutionary business model, MCCPDC sources its pharmaceuticals directly from manufacturers, effectively eliminating the cost-inflating middlemen. Further expanding its horizon, the company is also setting the stage to produce generic drugs—and potentially biosimilars—at a sprawling 22,000 square-foot facility currently under construction near Dallas, Texas.
In the previous year, MCCPDC proudly launched an online pharmacy, a venture that closely followed the establishment of its pharmacy benefit manager (PBM) operation. From its humble beginnings as a registered pharmaceutical wholesaler stocking a mere handful of drugs, the company now boasts over 350 generic drugs on its roster, all at significantly reduced prices. For the consumers' benefit, MCCPDC enforces a fixed markup of 15%, a nominal $3 pharmacy fee, and a $5 shipping charge. In an effort to uphold transparency, it discloses information about available medications, patient costs, and markups on its website, while partnering with Truepill pharmacy to fill prescriptions.
While the company currently deals exclusively in generic drugs, which make up only a fraction of overall pharmaceutical costs, Mark Cuban has expressed his intent to diversify the portfolio to include brand-name drugs. Furthermore, the company is contemplating the addition of insulin to its lineup. With the existing price for a vial of insulin reaching an exorbitant $95 for uninsured patients, MCCPDC aims to sell a 90-day supply of 12 vials for a mere $170. While this initiative may face hurdles in the form of complex biosimilars and manufacturing processes, the potential for significant impact remains undeniable.
MCCPDC proves particularly beneficial for uninsured individuals and those in the deductible phase of their health insurance. Although the company currently doesn't accept most health insurances, the intent to collaborate with insurers and smaller PBMs is evident. Indeed, MCCPDC has already announced partnerships with Capital Blue Cross and the PBM EmsanaRX, paving the way for customer discounts to count towards their deductible.
WOM Money Picks
Be a part of the winning team | 81% Success Rate.